14980 results for "cancer studies using rna-seq"

in 12.88 milliseconds.

• WGS and RNA-Seq data from a GBM patient PT-BK0248

  WGS and RNA-Seq data from a GBM patient PT-BK0248

  Dataset EGAD00001004228

• WGS and RNA-Seq data from a GBM patient PT-LS4891

  WGS and RNA-Seq data from a GBM patient PT-LS4891

  Dataset EGAD00001004252

• WGS and RNA-Seq data from a GBM patient PT-AB0029

  WGS and RNA-Seq data from a GBM patient PT-AB0029

  Dataset EGAD00001004221

• WGS and RNA-Seq data from a GBM patient PT-LR9369

  WGS and RNA-Seq data from a GBM patient PT-LR9369

  Dataset EGAD00001004251

• WGS and RNA-Seq data from a GBM patient PT-JP2405

  WGS and RNA-Seq data from a GBM patient PT-JP2405

  Dataset EGAD00001004247

• RNA-seq CLL

  RNA-seq of peripheral blood samples from CLL patients.

  Dataset EGAD00001001675

• WGS and RNA-Seq data from a GBM patient PT-JB1730

  WGS and RNA-Seq data from a GBM patient PT-JB1730

  Dataset EGAD00001004245

• RNA-seq sequence data from DNMT3A microcephalic dwarfism patients.

  RNA-seq data generated from cells from control individuals and individuals with de novo DNMT3A variants causing microcephalic dwarfism.

  Dataset EGAD00001004471

• Transcriptome profiling of 25 prostate tumor samples by RNA-Seq

  Transcriptome profiling of 25 prostate tumor samples by RNA-Seq

  Dataset EGAD00001003344

• RNA-seq data for ATLAS paper (123 patients)

  RNA-seq data of multi-region samples from PLANET 123 Patient cohort

  Dataset EGAD00001009859

• WGS and RNA-Seq data from a GBM patient PT-RL7940

  WGS and RNA-Seq data from a GBM patient PT-RL7940

  Dataset EGAD00001004258

• RNA-Seq files accompanying Genetic landscape of pediatric Rhabdomyosarcoma

  RNA-Seq files accompanying Genetic landscape of pediatric Rhabdomyosarcoma

  Dataset EGAD00001000878

• A Phase I Study With a Personalized Neoantigen Cancer Vaccine in Glioblastoma Multiforme

  Neoantigens, which are derived from tumor-specific protein-coding gene mutations, are exempt from central tolerance, can generate robust immune responses and function as bona fide antigens that facilitate tumor rejection. A strategy of using multi-epitope and personalized neoantigen vaccination has previously been tested in patients with high-risk melanoma. We demonstrated that this strategy is feasible for glioblastoma (GBM) which typically has a relatively low mutation load and an immunologically 'cold' tumor microenvironment. We conducted whole exome sequencing (WES) of tumor and normal cells from individual GBM patients to identify tumor-specific mutations. We assessed the expression of mutated alleles by RNA-sequencing of tumor, and used personalized neoantigen-targeting vaccines to immunize newly diagnosed GBM patients following surgical resection and conventional radiotherapy in a phase I/Ib study. Patients who did not receive dexamethasone, a highly potent corticosteroid that is frequently prescribed to treat cerebral oedema in GBM patients, generated circulating polyfunctional neoantigen-specific CD4+ and CD8+ T cell responses that were enriched in a memory phenotype and showed an increase in the number of tumor-infiltrating T cells. Using single-cell T cell receptor analysis, we provided an evidence that neoantigen-specific T cells from the peripheral blood can migrate into an intracranial GBM tumor. Neoantigen-targeting vaccines thus have the potential to favorably alter the immune environment of GBM.In order to discover cancer antigens derived from annotated and unannotated protein-coding regions of the genome, we carried out matched ribosome profiling (Ribo-Seq) on two GBM samples. We discovered novel or unannotated open reading frames (nuORFs) and their expression levels as well as somatic mutations within the nuORFs, which could be used to predict potential neoantigens.

  Study phs001519

• CLL RNA-seq

  This dataset contains Illumina stranded RNA-seq from of 19 chronic lymphocytic leukemia (CLL) patients with or without mutation in SF3B1, as well as 6 B cell samples from healthy individuals. RNA was extracted from CLL cells.

  Dataset EGAD50000000078

• RNA Seq Data

  Human melanoma samples were collected pre, on, and progression on BRAF inhibitor therapy. RNA was extracted and run on RNA-seq. This has provided insights into different categories of BRAF inhibitor resistance mechanisms.

  Dataset EGAD00001001306